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Human Cytomegalovirus pUL29/28 and pUL38 Repression of p53-
Regulated p21CIP1 and Caspase 1 Promoters during Infection
John P. Savaryn,a,b* Justin M. Reitsma,a,b Tarin M. Bigley,a,b Brian D. Halligan,b Zhikang Qian,c Dong Yu,c Scott S. Terhunea,b
Department of Microbiology and Molecular Geneticsa and Biotechnology and Bioengineering Center,b Medical College of Wisconsin, Milwaukee, Wisconsin, USA;
Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USAc
During infection by human cytomegalovirus (HCMV), the tumor suppressor protein p53, which promotes efficient viral gene
expression, is stabilized. However, the expression of numerous p53-responsive cellular genes is not upregulated. The molecular
mechanism used to manipulate the transcriptional activity of p53 during infection remains unclear. The HCMV proteins IE1,
IE2, pUL44, and pUL84 likely contribute to the regulation of p53. In this study, we used a discovery-based approach to identify
the protein targets of the HCMV protein pUL29/28 during infection. Previous studies have demonstrated that pUL29/28 regu-
lates viral gene expression by interacting with the chromatin remodeling complex NuRD. Here, we observed that pUL29/28 also
associates with p53, an additional deacetylase complex, and several HCMV proteins, including pUL38.We confirmed the inter-
action between p53 and pUL29/28 in both the presence and absence of infection. HCMV pUL29/28 with pUL38 altered the activ-
ity of the 53-regulatable p21CIP1 promoter. During infection, pUL29/28 and pUL38 contributed to the inhibition of p21CIP1 as
well as caspase 1 expression. The expression of several other p53-regulating genes was not altered. Infection using a UL29-defi-
cient virus resulted in increased p53 binding and histone H3 acetylation at the responsive promoters. Furthermore, expression
of pUL29/28 and its interacting partner pUL38 contributed to an increase in the steady-state protein levels of p53. This study
identified two additional HCMV proteins, pUL29/28 and pUL38, which participate in the complex regulation of p53 transcrip-
tional activity during infection.
Human cytomegalovirus (HCMV) is a member of the beta-herpesvirus family, which also includes human herpesviruses
6 and 7. Infection byHCMV is a leading cause of birth defects and
can cause severe disease upon immunosuppression (reviewed in
reference 1). HCMV disease in immunosuppressed individuals is
often successfully managed using the antiviral compound ganci-
clovir, valganciclovir, cidofovir, or foscarnet. Congenital HCMV
infection, however, remains a significant problem because of lim-
ited diagnostics and treatment options as well as the lack of com-
munity awareness (2). The initial infection leads to systemic viral
spread and a balance between latent and lytic replication cycles
among diverse cell types within the body. These complex replica-
tion cycles result in a persistent lifelong infection.
Successful HCMV infection involves viral proteins interacting
with and disconnecting cellular stress response pathways.Many of
these pathways and the associated proteins are also altered in can-
cers and are conserved targets among diverse herpesviruses. Ex-
amples include DAXX (death domain-associated protein) (3–6),
PML (promyelocytic leukemia protein) (7–11), IFI16 (interferon-
inducible protein 16) (12, 13), Tip60 (Tat-interactive protein, 60
kDa) (14, 15), and p53 (16–24). Upon infection, delivery of the
HCMV tegument protein pp71 (UL82) results in the degradation
of cellular DAXX and disruption of an intrinsic antiviral response
(3–6). The response is further influenced by the interaction be-
tween HCMV IE1 and PML (7–11). A second tegument protein,
pp65 (UL83), binds the nuclear pathogen sensor and transcrip-
tion factor IFI16 (25, 26), resulting in IFI16-dependent activation
of the HCMV major immediate early (MIE) promoter (12, 13).
Viral proteins also regulate the tumor suppressor protein Tip60
acetyltransferase (14, 15, 27). Tip60 participates in diverse path-
ways, including the activation of ATM (ataxia telangiectasia mu-
tated protein) following DNA damage (28). Expression of pUL27
causes the transient degradation of Tip60 at early times of infec-
tion, resulting in increased expression of the CDK (cyclin-depen-
dent kinase) inhibitor, p21CIP1 (15). Tip60 is also a target of
several herpesvirus kinases, including HCMV pUL97 (14).
In general, the cellular responses involving PML,DAXX, IFI16,
and Tip60 have all been demonstrated to influence the activities of
the transcription factor and tumor suppressor protein p53 (29–
32). As a central participant in stress responses, p53 is manipu-
lated by HCMV. The steady-state amount of p53 protein but not
RNA increases very early during infection (19, 20, 22). This stabi-
lization of p53 (33) occurs, in part, by HCMV IE2-mediated re-
pression of the E3 ubiquitin ligase protein MDM2 (20, 34). In
addition, p53 is phosphorylated on serine 15 and 20 during infec-
tion (35, 36), and these modifications are typically associated
with increased transcriptional activity. Expression of p53 contrib-
utes to efficient infection by influencing HCMV gene expression
(16–18, 21, 23, 24). Surprisingly, however, the majority of p53-
regulatable cellular genes are not induced (19). Reevaluation of
expression changes in known p53-responsive genes (37) frommi-
croarray studies on HCMV infected cells (38) identified only 8
genes that increased in expression at multiple times postinfection,
while 61 decreased or did not change within the first 24 h postin-
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fection (hpi) (see Table S1 in the supplemental material). The
HCMV proteins IE1, IE2, pUL44, and pUL84 participate in regu-
lating p53 by binding to and altering p53-mediated transcription
(22, 35, 39–44). In addition, regulation of p53 is partially achieved
by relocalization of a subpopulation of p53 to viral replication
centers within the nucleus (17). However, it is not clear whether
these events are sufficient for HCMV to control p53 transcrip-
tional activity during infection.
In this study, we observed that p53 also associates with the
HCMVprotein pUL29/28 during infection. This viral protein was
previously identified in proteomic-based screens involving
HCMV pUL38 (45) or cellular histone deacetylase 1 (HDAC1)
(46) as bait. Expression of pUL29/28 is observed as early as 6 hpi
and detected in sorbitol-pelleted virions, albeit at low levels
(47). pUL29/28 is distributed throughout the nucleus (47) and
associates with components of the HDAC1-containing nuclear
remodeling and deacetylase (NuRD) complex during infection
(46). Disruption of pUL29/28 (47–49) or components of
NuRD result in decreased HCMV gene expression and genome
replication (46). These results implicate pUL29/28 to be a tran-
scriptional regulator.
The aim of this study was to more accurately define pUL29/28
binding partners during infection and determine the functional
relevance of the interactions. Using pUL29/28 as bait, we discov-
ered interactions with cellular p53 as well as two deacetylase com-
plexes and several additional HCMV proteins. Expression of
pUL29/28 with its binding partner pUL38 altered RNA levels for
two of the six p53-regulatable cellular genes examined. In the ab-
sence of UL29, we observed changes in p53 binding as well as
histone H3 acetylation at the responsive promoters during infec-
tion. Overall, our studies confirm the role of pUL29/28 as a tran-
scriptional regulator and identify the tumor suppressor protein
p53 and two p53-regulatable cellular genes as additional targets of
its activity.
MATERIALS AND METHODS
Biological reagents. The recombinant HCMV viruses ADin29FLAG,
ADin28FLAG-C, and ADdel38 (ADdlUL38) were previously generated
(47, 50) using AD169 BAC (ADwt virus). ADdel29 virus was con-
structed using BAC recombineering (51, 52) where the UL29 open
reading frame (ORF) was replaced by the galK gene using BAC re-
combineering (5=-GCGGGTCGCCGAGGCTACTGCTGCTTCTGCTT
TTTTGTCTCCTGTGGATCGTCGCGGACTGCCGGCCCTGTTGACA
ATTAATCATCGGCA-3= and 5=-GTCTCAAACACGCTACTTTCGGTT
ATAAAAACACCGTCGCCCTATTTCTGGGCGCGTGTACACTGATG
ACTCAGCACTGTCCTGCTCCTT-3=). Viral stocks were prepared by
either transfecting BAC DNA or infecting primary human fibroblasts.
Concentrated stocks were obtained by ultracentrifugation through a sor-
bitol cushion (20% D-sorbitol, 50 mM Tris-HCl [pH 7.2], 1 mMMgCl2)
at 55,000  g for 1 to 2 h. Titers of viral stocks were determined using a
50% tissue culture infectious dose (TCID50) assay. Human fibroblasts
were maintained in 96-well culture plates and infected with 10-fold serial
dilutions of the viral stock. After an incubation period of approximately 2
weeks, the cells were fixed and stained for HCMV pUL123 (IE1). Titers
were determined by counting the number of pUL123-positive wells per
dilution series in the TCID50 assay and defined as infectious units (IU) per
ml. The viral titers from experimental samples were determined by infect-
ing fibroblasts with serial dilutions of the culture supernatants, fixing, and
staining for pUL123 at 48 hpi.
Human foreskin fibroblasts, U-2 OS osteosarcoma cells, and 293T
Phoenix cells were propagated in Dulbecco’s modified Eagle medium
(DMEM) (Life Technologies, Carlsbad, CA) supplemented with 7 to 10%
fetal bovine serum (non-USA-qualified FBS [USDA-approved non-USA
FBS]) (Life Technologies, Carlsbad, CA) and 1% penicillin-streptomycin
(Life Technologies, Carlsbad, CA). For experiments where aspects of in-
fection were compared between viruses, cells were serum starved prior to
infection for approximately 24 to 48 h. For nutrient restriction experi-
ments, fibroblasts were infected at a multiplicity of 6 IU per cell in stan-
dard medium (DMEM, 7% FBS, and 25 mM glucose) for 1 h. The cells
were then washed with phosphate-buffered saline (PBS) and replenished
with either standard medium or restrictive medium containing DMEM,
5.6 mM glucose, and no FBS.
The luciferase plasmids containing the p21Cip1 promoter was kind
gifts from B. Vogelstein (The Johns Hopkins University School of Medi-
cine) (53, 54). The pCGN-UL29/28HA plasmid has been previously de-
scribed (47). The pCIcchp53FLAG plasmid was a kind gift from L. Cirillo
(TheMedical College ofWisconsin) (55) and pEGFP fromClontech Lab-
oratories, Inc. (Mountain View, CA). The following antibodies were used
in studies for Western blot (WB), immunoprecipitation (IP), or immu-
nofluorescence analysis (IF): mouse anti-FLAGM2 (WB, IP, IF) (Sigma-
Aldrich, St. Louis, MO), mouse anti-p53 clone DO-1 (WB, IP, IF) (Santa
Cruz Biotechnology, Santa Cruz, CA; Sigma-Aldrich, St. Louis, MO),
mouse anti-GAPDH clone 0411 (WB) (Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit anti-Myc clone 71D10 (WB) (Cell Signaling Technol-
ogy, Danvers, MA), mouse anti-HDAC3 clone 3G6 (WB, IP) (EMD-Mil-
lipore, Billerica, MA), mouse anti-hemagglutinin (HA) clone HA-7 (WB,
IP) (Sigma-Aldrich, St. Louis, MO), rabbit anti-FLAG (WB) (Sigma-Al-
drich, St. Louis, MO), mouse anti-p21Cip1 clone CP74 (WB) (EMD-
Millipore, Billerica,MA),mouse anti-21Cip1 clone F-5 (WB) (Santa Cruz
Biotechnology, Santa Cruz, CA), mouse anti-ICP36 clone 10D8 (WB)
(Virusys Corporation, Taneytown, MD), rabbit anti-p53 acetyl (K382)
(WB) (Epitomics, Burlingame, CA), mouse anti-beta actin clone AC-15
(WB) (Abcam, Cambridge, MA), and mouse control IgG (Santa Cruz
Biotechnology, Santa Cruz, CA). Themouse anti-pUL38 clone 8D6 (WB)
(50), andmouse anti-pUL123 clone 1B12 (WB)were generously provided
by TomShenk (PrincetonUniversity, Princeton, NJ). Secondary antibod-
ies forWestern blot analysis were goat anti-mouse IgG–HRP (horseradish
peroxidase) and donkey anti-rabbit IgG–HRP (Jackson Immuno-
Research, West Grove, PA), and those for immunofluorescences were
goat anti-mouse IgG (heavy plus light chain [HL])–Alexa Fluor 488 and
donkey anti-mouse IgG (HL)–Alexa Fluor 488 (Life Technologies,
Carlsbad, CA).
Mass spectrometry analysis. Primary foreskin fibroblasts were in-
fected at an MOI of 3 using ADin29FLAG and harvested at 24 hpi as
previously described (45). Fractionated cell powder was resuspended in
lysis buffer [20 mMHEPES-KOH (pH 7.4), 110mMpotassium acetate, 2
mM MgCl2, 0.1% (vol/vol) Tween 20, 1.0% (vol/vol) Triton X-100, 250
mMNaCl, and protease inhibitors (Roche Applied Science, Indianapolis,
IN)]. Protein complexes were isolated using mouse anti-FLAG M2 anti-
body conjugated to Dynabeads M-270 epoxy (Life Technologies, Carls-
bad, CA) for approximately 1 h, eluted, dried, and resuspended in SDS-
PAGE loading buffer. Samples were alkylated with iodoacetamide and
separated by SDS–10%PAGE. The entire lane was cut into approximately
4 mm sections and processed as previously described (45). The isolated
tryptic peptides were dried, resuspended in 5% acetonitrile and 0.1%
formic acid, and identified by liquid chromatography-tandemmass spec-
trometry (LC-MS/MS) using anESI-LTQXLmass spectrometer (Thermo
Fisher Scientific, Waltham, MA). Peptide identification was carried out
using the search algorithm SEQUEST and a combined human cytomeg-
alovirus and human protein database with a global false discovery rate of
5%. The results were evaluated using the free software Visualize (56).
Proteins which bound to the antibody-conjugated beads were also iden-
tified following infection with wild-type HCMV as previously described
(15), and this information controlled for nonspecific interactions.
Analysis of protein and nucleic acid. For Western blot analysis of
steady-state protein levels, cells were lysed in an SDS lysis buffer (1% SDS,
50 mM Tris [pH 7.4]). Protein samples were resolved using sodium do-
Savaryn et al.
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decyl sulfate–10% polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred by semidry transfer to Protran nitrocellulose membranes
(Whatman Inc., Piscataway, NJ). The membrane was blocked with 5%
milk in phosphate-buffered saline (PBS) containing 0.1%Tween 20 (PBS-
T). Themembranewas incubatedwith primary antibody diluted in PBS-T
containing 3% bovine serum albumin (BSA) followed by a secondary
antibody conjugated to HRP. The antibodies were detected using an en-
hanced chemiluminescence (ECL) or ECL Plus reagent (GE Healthcare,
Piscataway, NJ) and filmor FluorChemHD2 (Proteinsimple, Santa Clara,
CA), and a ChemiDoc system (Bio-Rad, Hercules, CA) was used for pro-
tein quantification. For immunoprecipitation experiments, cells were
lysed in an NP-40 lysis buffer (0.1 to 0.5% NP-40, 50 mM Tris, 150 mM
NaCl, 1mMEDTA [pH7.4]). Immunoprecipitationwas completed using
either protein A/G Plus agarose (Santa Cruz Biotechnology, Santa Cruz,
CA) or Dynabeads protein G (Life Technologies, Carlsbad, CA). Lysates
were precleared for 30 min at 4°C using beads in the absence of antibody.
Samples were incubated with antibody for 1 to 2 h at 4°C followed by the
addition of beads for 1 h at 4°C. The beads were washed three times with
lysis buffer and resuspended in Laemmli sample buffer. The samples along
with lysate controls obtained prior to immunoprecipitation were evalu-
ated by Western blotting.
For immunofluorescence microscopy, cells were grown on coverslips,
infected at a multiplicity of 4, fixed using 2% paraformaldehyde, perme-
abilized using 0.1% Triton X-100, and blocked using BSA dissolved in
PBS-T. Fixed cells were incubated for 1 h using primary antibody against
p53 diluted in PBS-T and BSA, washed with PBS-T, and incubated with a
fluorophore-coupled secondary antibody. Finally, coverslips were
mounted using SlowFade gold antifade reagent (Life Technologies, Carls-
bad, CA).
Quantification of cellular and viral RNA was completed using quan-
titative reverse transcriptase PCR (qRT-PCR). Total RNA was collected
using TRIzol reagent (Life Technologies, Carlsbad, CA), and cDNA was
synthesized using 1 to 2 g of DNase-treated RNA, random hexamers,
and SuperScript III reverse transcriptase (Life Technologies, Carlsbad,
CA). Following cDNA synthesis, qPCR was performed using primers de-
signed against the genes of interest. Primers for p21CIP1 and GAPDH
were published previously (15). Additional primers (Integrated DNA
Technologies, Inc., Coralville, IA) included TSC2 (5=-GGATGATAGGG
CAGATTTGTGAA-3=, 5=-ACCGCCTTCCAGAGTGCTT-3=), PUMA
(5=-TGGAGGGTCCTGTACAATCTCA-3=, 5=-TCTGTGGCCCCTGGG
TAA-3=), CASP1 (5=-CATCACAGGCATGACAATGCTGCT-3=, 5=-TGC
CTTCCCGAATACCAT GAGACA-3=), BIRC5 (5=-TCTGTCAGCCCAA
CCTTCACATCT-3=, 5=-TGTAACAATCCACCCTGCAGCTCT-3=),
IGFBP3 (5=-AGTTCCTCAATGTGCTGAGTCCCA-3=, 5=-AGGCTGCC
CATACTTATCCACACA-3=), MMP2 (5=-AGAAGGATGGCAAGTACG
GCTTCT-3=, 5=-AGTGGTGCAGCTGTCATAGGATGT-3=), andMDM2
(5=-CTATTGGAAATGCACTTCATGCA-3=, 5=-CGAAGGGCCCAACA
TCTGT-3=). Quantification was completed using FastStart universal
SYBR green master mix (Roche Applied Science, Indianapolis, IN) and a
7900HT fast real-time PCR system (Life Technologies, Carlsbad, CA). A
standard curve consisting of 10-fold serial dilutions of one sample was
used to determine relative abundance.
Cellular and viral DNA levels were determined by quantitative PCR
(qPCR). Cells were harvested and incubated overnight inDNA lysis buffer
(400 mM NaCl, 10 mM Tris [pH 8.0], 10 mM EDTA, 0.1 mg/ml of pro-
teinase K, and 0.2% SDS) at 37°C. DNA was extracted using phenol-
chloroform, treated with RNase A for 1 h at 37°C, and ethanol precipi-
tated. qPCR was performed using primers directed against either viral
(15) or cellular DNA. For these studies, we used primers targeting se-
quences located within the cellular gene BAX (5=-TCCCCCCGAGAGGT
GTTTT-3= and 5=-CGGCCCCAGTTGAAGTTG-3=). A standard curve
consisting of 10-fold serial dilutions was used to determine relative abun-
dance.
Luciferase reporter assays. U-2 OS cells or U-2 OS cells expressing
HCMV pUL38 growing in 12-well culture plates were transfected with
reporter and expression plasmids using Fugene 6 transfection reagent
(Roche Applied Science, Indianapolis, IN). Amounts of luciferase re-
porter vectors used ranged from 50 to 200 ng per well, and amounts of
expression plasmids ranged from 1 to 100 ng per well. The cells were
harvested at 2 days posttransfection, and relative light units (RLU) were
measured within each lysate using the luciferase assay system (Promega
Corp, Madison, WI) as previously described (46, 47). The RLUs were
quantified using a Victor 3V multilabel plate reader (PerkinElmer, Inc.,
Waltham, MA) with a measurement time of 10 s.
Cell cycle analysis.Quantification of cell cycle phases was completed
as previously described (15) using U-2 OS cells or U-2 OS cells expressing
HCMV pUL38. Both cell types were transfected with 10 g of pCGN-
pUL29/28HA expression plasmid using Fugene 6 transfection reagent
(Roche Applied Science, Indianapolis, IN) following the manufacturer’s
instructions. The cells, culturing conditions, and plasmid were as de-
scribed above (see “Biological reagents”). At 24 h posttransfection, the
cells were either untreated (unsynchronized) or treated (synchronized)
with 75 ng/ml nocodazole (Sigma-Aldrich, St. Louis, MO) for 16 h. The
cells were then collected, fixed using 70% ice-cold ethanol, and stained
using amouse anti-HA antibody (Sigma-Aldrich, St. Louis,MO) followed
by rabbit anti-mouse IgG antibody conjugated to Alexa Fluor 488 dye
(Life Technologies, Carlsbad, CA). To measure DNA content, the cells
were incubated for 30 min in Guava cell cycle reagent (EMD Millipore,
Billerica, MA) at room temperature in the dark. Flow cytometry was per-
formed using a Guava EasyCyte mini-flow cytometer system (EMD Mil-
lipore, Billerica, MA). The DNA content of positively and negatively HA-
stained cells was determined by gating on each population using FlowJo
analysis software (Tree Star, Ashland, OR).
Chromatin immunoprecipitation assay. For chromatin immuno-
precipitation (ChIP) experiments, 5 106 human fibroblasts were plated
onto one 150-mm dish as described in “Biological reagents.” Cells were
synchronized using DMEM containing 0.5% FBS for 48 h and were mock
infected, infected at an MOI of 6 infectious units per cell using ADwt or
ADdel29 virus, or treated with 10Mnutlin-3 (Sigma-Aldrich, St. Louis,
MO) in DMEM containing 7% FBS. Cells were fixed at 18 hpi in 1%
ChIP-grade formaldehyde (Thermo Fisher Scientific, Waltham, MA) for
10min and neutralized with 125mMglycine for 5min. Cells were washed
three times with ice cold phosphate-buffered saline, scraped, collected,
and lysed in 500 l SDS lysis buffer (1% sodium dodecyl sulfate, 10 mM
EDTA, 50mMTris-HCl [pH 8.1]) containing Completemini-EDTA-free
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN).
Lysates were sonicated to an average size of 1 kbp using a microtip soni-
cator. Insoluble material was removed by centrifugation at 18,000 g at
4°C for 10min. A fraction of supernatant was kept for the input measure-
ment and to test shearing efficiency.
The resulting supernatant was diluted with 5 volumes of ChIP buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 1.67 M Tris-HCl [pH
8.1], 176 mMNaCl) and incubated with 10 g antibody overnight at 4°C
with rotation. The antibodies used were mouse anti-p53 clone DO-1
(Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-acetyl-histone 3
lys9 (Millipore, Billerica, MA), and normal mouse IgG (Santa Cruz Bio-
technology, Santa Cruz, CA). Antibody complexes were precipitated with
60l Dynabeads protein G (Life Technologies, Carlsbad, CA) for 2 h with
rotation at 4°C. The bound complexes were collected using a magnet and
washed once with low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl [pH 8.1], 150 mM NaCl), once with high-salt
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH
8.1], 500 mM NaCl), once with LiCl wash (250 mM LiCl, 1% Igepal-
CA630, 1% sodiumdeoxycholate, 1mMEDTA), and twicewith TE buffer
(10 mM Tris-HCl [pH 8.1], 1 mM EDTA), then eluted twice in 250 l
elution buffer (40mMNaHCO3, 1% SDS, 10mMdithiothreitol) at room
temperature for 15 min. The beads were removed, and the eluate was
reverse cross-linked using a final concentration of 4%NaCl at 65°C for 12
h. Proteins within the eluate were digested in 10 mM EDTA and 40 mM
Tris-HCl (pH 6.5) using 40 g proteinase K (Roche Applied Science,
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Indianapolis, IN) at 45°C for 1 h. DNAwas isolated using a gel-PCRDNA
fragment extraction kit (IBI Scientific, Peosta, IA) per manufacturer pro-
tocols and eluted using 30l EB elution buffer provided in the kit. Cellular
DNA levels were determined using quantitative PCR with sequence-specific
primers. The PCRmixture was 5l 2 FastStart universal SYBR greenmas-
ter mix (Roche Applied Science, Indianapolis, IN), 3.6 l H2O, 0.2 l of
each 100 Mprimer stock, and 1 l of sample. PCR primers detected the
3= p53 response element (RE) in the p21CIP1 promoter (5=-CTCTCCTC
CCCGAGGTCA-3=, 5=-ACATCTCACGCTGCTCACAGTCT-3=), the 5=
RE in the p21CIP1 promoter (5=-AGCAGGCTCTGGCTCTGATT-3=, 5=-
CAAAATAGCCACCAGCCTCTTCT-3=), caspase 1 promoter (5=-GGCC
TGTACATCTATTGG-3=, 5=-GATCTATCCAAGGGCTGGTG-3=), PUMA
promoter (5=-GCGAGACTGTGGCCTTGTGT-3=, 5=-CGTTCCAGGGT
CCACAAAGT-3=) (57), and exon 6 of GAPDH (5=-CCTCACAGTTGCC
ATGTA-3=, 5=-CATGGTACATGACAAGGTG-3=).
RESULTS
HCMV pUL29/28 interacts with cellular p53 during infection.
HCMV pUL29/28 interacts with pUL38 (45), cellular HDAC1
(histone deacetylase 1) and MTA2 (metastasis-associated protein
2) (46) during infection. These interactions were identified using
pUL38 and HDAC1 as bait during immunoisolation of protein
complexes and identification by mass spectrometry. To more ac-
curately define pUL29/28 binding partners, we elected to use
pUL29/28 as the bait protein. Using the ADin29FLAG virus (47),
which expresses pUL29/28 in-frame with the FLAG epitope at the
amino terminus, we infected primary fibroblasts at 3 infectious
units (IU)/cell. At 24 hpi, protein complexes were isolated using
an antibody against the FLAG epitope and further fractionated by
their masses on an SDS-PAGE gel. The resulting proteins were
identified by liquid chromatography-tandem mass spectrometry
(LC-MS/MS). Proteins identified as binding nonspecifically to the
reagents using lysates from AD169 wild-type (ADwt)-infected
cells were removed from the results (15). In Table 1, we list puta-
tive binding proteins which were identified by at least 7 unique
peptides from the combined results of three biological replicate
experiments. The complete list of proteins defined by at least 3
peptides, minus the nonspecific interactions, is presented in Table
S2 in the supplemental material.
The resulting data confirmed the previously observed inter-
actions with the HDAC1- and MTA2-containing NuRD com-
plex (46). However, unlike in previous studies, here we de-
tected most of the proteins that define this chromatin
remodeling complex (Table 1) (reviewed in reference 58). In
addition, we observed protein components of the nuclear re-
ceptor corepressor (N-CoR) deacetylase complex (Table 1;
also, see Table S2 in the supplemental material) (59). We also
detected the tumor suppressor protein p53 and several p53-
TABLE 1 Putative CMV pUL29/28- and pUL29-interacting proteins at 24 hpi
Type
UniProt
accession no.
HGNCa
symbol Name Complexb p53b
No. of peptides
% CoverageUnique Total
Viral P16764 UL29 NuRD 20 564 48.89
P16727 UL84 x 13 16 29.69
P16761 UL25 10 13 24.24
P16779 UL38 NuRD 9 66 38.07
P16847 UL28 NuRD 9 60 36.94
Cellular O94776 MTA2 Metastasis associated 1 family, member 2 NuRD x 32 162 53.89
Q9BZK7 TBL1XR1 Transducin (beta)-like 1 X-linked receptor 1 N-CoR 25 271 60.89
O75376 NCOR1 Nuclear receptor corepressor 1 N-CoR x 22 56 10.66
Q86YP4 GATAD2A GATA zinc finger domain containing 2A NuRD 22 39 46.92
P15924 DSP Desmoplakin 19 22 10.10
Q9BTC8 MTA3 Metastasis associated 1 family, member 3 NuRD 17 62 33.00
O60907 TBL1X Transducin (beta)-like 1X-linked N-CoR 16 112 41.44
Q14839 CHD4 Chromodomain helicase DNA binding protein 4 NuRD 16 38 9.88
Q8WXI9 GATAD2B GATA zinc finger domain containing 2B NuRD x 15 61 34.40
Q13330 MTA1 Metastasis associated 1 NuRD x 15 54 25.59
Q92769 HDAC2 Histone deacetylase 2 NuRD x 13 102 32.79
Q09028 RBBP4 Retinoblastoma binding protein 4 NuRD 12 113 36.71
O15379 HDAC3 Histone deacetylase 3 N-CoR 12 39 31.54
Q9Y618 NCOR2 Nuclear receptor corepressor 2 N-CoR 12 20 6.36
O00505 KPNA3 Karyopherin alpha 3 (importin alpha 4) x 10 18 24.57
Q16576 RBBP7 Retinoblastoma-binding protein 7 NuRD 9 90 21.88
O95983 MBD3 Methyl-CpG binding domain protein 3 NuRD 9 20 28.87
Q9BQ87 TBL1Y Transducin (beta)-like 1, Y-linked N-CoR 8 87 21.07
Q9NP68 TP53 Tumor protein p53 NuRD/NCoR x 8 11 23.92
P13667 PDIA4 Protein disulfide isomerase family A, member 4 7 16 15.35
Q9UBB5 MBD2 Methyl-CpG binding domain protein 2 NuRD x 7 15 18.25
P02786 TFRC Transferrin receptor (p90, CD71) 7 12 10.92
O00629 KPNA4 Karyopherin alpha 4 (importin alpha 3) x 7 10 17.27
P14923 JUP Junction plakoglobin 7 8 11.02
P04181 OAT Ornithine aminotransferase 7 7 21.87
a HGNC, HUGO Gene Nomenclature Committee.
b Published interactions.
Savaryn et al.
2466 jvi.asm.org Journal of Virology
 o
n
 D
ecem
ber 2, 2014 by W
ashington University in St. Louis
http://jvi.asm.org/
D
ow
nloaded from
 
binding proteins, including importin  (KPNA3, KPNA4) (60)
and proteins within both the NuRD (61) and N-CoR (62) com-
plexes (Table 1). Finally, the viral proteins pUL25, pUL84, and
pUL38 were observed. HCMV pUL84 has been previously
demonstrated to associate with p53, the NuRD component
RBBP4, and importin  (Table 1) (42, 63, 64). Our results
suggest that pUL29/28 interacts with multiple viral and cellular
proteins at 24 hpi, including the tumor suppressor protein p53.
Because several of the identified proteins are known regulators
of p53 (Table 1), and p53 is important for HCMV replication, we
focused the remaining studies on determining the relationship
between pUL29/28 and p53. First, to confirm the interaction, we
infected fibroblasts with ADin28FLAG-C, which contains a FLAG
epitope at the carboxyl terminus of pUL29/28 (47). At 24 hpi, we
immunoprecipitated protein complexes using an antibody against
p53 and completed a Western blot using an antibody against the
FLAG epitope placed in pUL29/28. As seen in Fig. 1A, we detected
a protein at the correct molecular weight of pUL29/28 using ly-
sates from ADin28FLAG-C- but not ADwt-infected cells. We did
not observe this protein using a control antibody against the HA
(hemagglutinin) epitope (Fig. 1A). Based upon these results, we
conclude that pUL29/28 does associate with p53 during infection.
To determine whether the interaction occurs in the absence of
infection, we transfected cells with a p53FLAG expression plasmid
and either an empty or a pUL29/28HA expression plasmid. We
elected to use p53FLAG because the antibody heavy chain pre-
vented detection of endogenous p53. Constructs were introduced
into U-2 OS osteosarcoma cells which express pUL38 (U2OS-
UL38 cells) (46, 47). We evaluated interactions by immunopre-
cipitating p53FLAG with an antibody against the FLAG epitope
and Western blot analysis using an antibody against HA. We ob-
served an interaction between p53 and pUL29/28 (Fig. 1B) as well
as the smaller pUL29 protein (47). Furthermore, we detected
pUL38 within these complexes (Fig. 1B). Interestingly, pUL38
failed to associate with p53 in the absence of expression of either
UL29 isoforms (Fig. 1B). Our data indicate that pUL29/28 and
pUL38 likely interact with p53 and suggest that no additional viral
proteins are necessary for the event.
Expression of pUL29/28 and pUL38 alters expression of the
p53-regulatable p21CIP1 promoter. We next asked whether
pUL29/28 could influence p53-regulated gene expression.We ini-
tiated these studies by determining changes in promoter activity
using a luciferase reporter. Increasing amounts of pUL29/28HA
expression plasmid were transfected into U2OS cells along with a
reporter regulated by the p21CIP1 promoter (CDK-interacting
protein 1) (53) (Fig. 2A). Luciferase activity was determined for
each sample and presented relative to the empty plasmid control
as previously described (46, 47). Following transfection, similar
levels of luciferase DNA relative to cellular DNAwere observed by
qPCR (data not shown). At the largest amount of pUL29/28HA
FIG 1 HCMVpUL29/28 and pUL38 interact with cellular p53. (A) Fibroblasts
were infected at an MOI of 6 with ADwt (wt) or ADin28FLAG-C (in28FLAG-
C). Immunoprecipitation was performed at 24 hpi from whole-cell lysates
using an antibody against p53 or the HA epitope. Western blotting was per-
formed using antibodies directed against the indicated proteins. (B) U2OS
cells stably expressing pUL38 (U2OS-pUL38) were transfected with p53FLAG
and either empty pCGN, pUL29/28HA, or pUL29HA. Immunoprecipitation
was performed at 48 h posttransfection using whole-cell lysates and an anti-
body against the FLAG epitope. Western blot analysis was completed using
antibodies against the indicated proteins.
FIG 2 Expression ofHCMVpUL29/28 and pUL38 alters p53-regulatable gene
expression in the absence of infection. (A) Control U2OS or U2OS-pUL38
(pUL38) were transfected with a plasmid containing the p21CIP1 promoter
driving luciferase along with 1.0, 10.0, and 100.0 ng of either empty pCGN or
pUL29/28 plasmidDNA. Relative luciferase activity wasmeasured at 48 h after
transfection. The data are means for two replicate samples standard devia-
tions. Statistical analysis was performed using Student’s t test (**, P  0.01).
(B) The U2OS and U2OS-pUL38 (pUL38) cells were either transfected with
empty vector or pUL29/28, or treated with nutlin-3 for 24 h. Cells were har-
vested 48 h posttransfection. Western blot analysis was performed using anti-
bodies against the indicated proteins. (C) U2OS cells were transfected with
pUL29/28HAexpression vector. At 40 h posttransfection, the cells were treated
with or without nocodazole to synchronize the population. Cells were stained
using antibody against the HA epitope and propidium iodide, and DNA con-
tent was measured by flow cytometry. The data are displayed as percentages of
cells in each phase of cell cycle and are the means from two biological experi-
ments standard errors of themeans. Statistical analysis was performed using
Student’s t test (*, P 0.05; **, P 0.01).
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plasmid used, we observed an average 7.1-fold increase in lucifer-
ase activity (Fig. 2A). To determine the contribution of pUL38, we
also completed the studies using U2OS-UL38 cells. We have pre-
viously demonstrated that pUL38 does not affect pUL29/28 pro-
tein expression levels (46). Furthermore, we did not observe dif-
ferences in luciferase activity betweenU2OS andU2OS-UL38 cells
receiving empty vector (Fig. 2A). Transfection of the pUL29/28
expression plasmid into U2OS-UL38 cells resulted in only a 2.8-
fold increase in p21CIP1 promoter activity (Fig. 2A). These obser-
vations suggest that pUL29/28 does influence p21CIP1promoter
activity but that pUL38 inhibits maximal pUL29/28-mediated ac-
tivation of the promoter.
In addition to promoter activity, we evaluated changes in en-
dogenous p21CIP1 levels by Western blotting in U2OS cells. We
elected to evaluate protein expression in order to detect p53 levels
in the experiments. Transfection of the pUL29/28 plasmid re-
sulted in a consistent increase in both p53 andp21CIP1 expression
levels compared to vector control (Fig. 2B, lanes 1 and 2). For a
positive control, we treatedU2OS cells with nutlin-3 which inhib-
its the MDM2 E3 ligase and stabilizes p53 (65). We observed ro-
bust increases in p53 and p21CIP1 protein levels following treat-
ment with nutlin-3 (Fig. 2B, lanes 1 and 3). In the U2OS-UL38
cells alone, we observed elevated levels of p53 compared to U2OS
cells (Fig. 2B, lane 1 and 4). Following expression of pUL29/28, we
detected an additional increase in p53which approached the levels
observed in the nutlin-treated control (Fig. 2B, lanes 5 and 6).
Surprisingly, however, the level of p21CIP1 remained low in spite
of the increase in p53. These changes follow the pattern observed
using the reporter plasmids (Fig. 2A). Furthermore, our data sug-
gest that expression of pUL38 and pUL29/28 causes an increase in
a population of p53 which is not capable of inducing p21CIP1
expression.
The cyclin-dependent kinase inhibitor p21CIP1 plays a down-
stream role in p53-dependent cell cycle arrest. To provide addi-
tional support for the idea that pUL29/28 and pUL38 influence
p53 activities and p21CIP1 expression, we evaluated relative
changes in the cell cycle. We transfected either U2OS or U2OS-
UL38 cells with the pUL29/28 expression plasmid. Following syn-
chronization in G2/M by nocodazole treatment, 88% of the un-
transfected control cells were in G2/M, as determined by flow
cytometry (Fig. 2C). In contrast, only 31% of the pUL29/28-pos-
itive cells were found in G2/M, while 60%were in G0/G1 (Fig. 2C).
In an unsynchronized population, we again observed 63% of
pUL29/28-expressing U2OS cells were in G0/G1 (Fig. 2C). These
data suggest that expression of pUL29/28 promotes cell cycle ar-
rest in G0/G1, which is consistent with elevated levels of p21CIP1.
In pUL38- and pUL29/28-expressing cells, however, we detected
39%of cells in G0/G1 (Fig. 2C). Expression of pUL38 alone had no
influence on the cell cycle (Fig. 2C). Although cell cycle control is
complex, these results correlate with the observed reduction in
p21CIP1 upon expression of both pUL29/28 and pUL38 (Fig. 2B,
lanes 2 and 5) and elevated levels of p53 (Fig. 2B, lane 5).
Our studies show that in the absence of HCMV infection and
other viral proteins, expression of pUL29/28 can induce the p53-
regulatable p21CIP1 promoter and p21CIP1 protein expression.
However, the response is significantly dampened upon coexpres-
sion of pUL38 with pUL29/28. Furthermore, expression of both
viral proteins together appears to increase the levels p53 without a
subsequent increase in p21CIP1 expression.
HCMVpUL29/28 andpUL38 are necessary to inhibit expres-
sion of a subset of p53-regulatable genes during infection. The
cellular environment during HCMV infection is substantially
more complex than that of uninfected cells involving the manip-
ulation of diverse cellular processes. Therefore, we quantified
changes in a subset of p53-regulatable genes following infection by
either ADwt or a UL29-deficient virus, ADdel29. In addition to
p21CIP1, we evaluated expression of CASP1 (caspase 1), BIRC5
(baculoviral IAP repeat containing 5), MDM2 (mdm2 p53 bind-
ing protein homolog), TSC2 (tuberous sclerosis 2), PUMA (p53
upregulated modulator of apoptosis), IGFBP3 (insulin-like
growth factor binding protein 3), andMMP2 (matrixmetallopep-
tidase 2) (37) using sequence-specific primers and quantitative
RT-PCR (Fig. 3). The experiments were completed by infecting
fibroblasts that had been synchronized by serum starvation with
either ADwt or ADdel29 virus at a multiplicity of 6 IU/cell. We
harvested total RNA at 5 and 18 hpi and determined expression
changes using relative quantification with a standard curve for
each primer pair and normalizing to GAPDH expression. Based
upon the results of our studies in U2OS cells, we had predicted
that a UL29-deficient viral infection would express reduced levels
of p53-regulatable genes compared to an infection with wild-type
virus. However, in contrast to our prediction, we observed in-
creased expression at 18 hpi (Fig. 3A). Expression of p21CIP1 as
well as CASP1 was on average 2.8- and 5.3-fold higher, respec-
tively, during infection with ADdel29 than during infection with
ADwt (Fig. 3A). Although statistically significant, the change in
IGFBP3 was less than 2-fold (Fig. 3A). Also, surprisingly, we did
not observe statistically significant differences in gene expression
for the other genes (Fig. 3B) between the two infections. Our data
demonstrate that infection in the absence of the UL29ORF results
in 2-fold-increased expression of only two of the eight p53-
regulatable genes examined.
Disruption of the UL29 gene results in both altered viral gene
expression and DNA replication using a low MOI (47). To deter-
mine whether the changes in p21CIP1 and CASP1 were possibly
due to a lag in the replication cycle, we quantified expression over
a time course using a high MOI. As shown in Fig. 4A, expression
levels of these genes remained elevated in ADdel29-infected cells
compared to ADwt as late as 48 hpi. At the protein level, p21CIP1
was higher duringADdel29 infection compared towild-type start-
ing at 28 hpi (Fig. 4B). Dependent on the specific time point, we
also observed reduced levels of p53 in the absence of UL29 (Fig.
4B). We did detect similar levels of expression for the viral pro-
teins pUL123 and pUL44 between viruses under high-MOI con-
ditions (Fig. 4B). These data suggest that the changes are not the
result of a lag in the replication cycle.
Cellular p53 and p53-regulated gene expression are influenced
by diverse forms of stress, including nutrient stress (66). Further-
more, pUL38 has been demonstrated to regulate the nutrient-
sensitive mTOR signaling pathway (45). We next determined
whether pUL29/28 could regulate p53 and p21CIP1 expression
following perturbation usingmedium lacking serum and contain-
ing reduced levels of glucose. Fibroblasts were synchronized by
removing serum for 24 h prior to infection, which resulted in
elevated levels of p21CIP1 at the time of infection (Fig. 4C). Fol-
lowing infection for 1 h in 25 mM glucose and 7% serum (high-
nutrient conditions), cultures were placed in either the same high-
nutrient conditions or moved to stressed conditions defined by
5.6 mM glucose and no serum (low-nutrient conditions). Using
Savaryn et al.
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Western blot analysis, we observed reduced levels of both p53 and
p21CIP1 under low-nutrient conditions at 8 and 21 hpi for both
ADwt and ADdel29 viral infections (Fig. 4C). However, expres-
sion of p21CIP1 decreased in ADwt- but not in ADdel29-infected
cells at 44 hpi regardless of medium conditions (Fig. 4C). HCMV
pUL123 protein levels appeared to be unaffected (Fig. 4C). Our
data suggest that pUL29/28 negatively regulates p21CIP1 expres-
sion independently of perturbation using nutrient stress.
To determine the impact of the pUL29/28-binding protein
pUL38 on gene expression, we quantified expression of p21CIP1
and CASP1 expression from infected cells at 18 hpi using either
ADwt or a UL38-deficient virus, ADdlUL38 (50). Expression of
both genes was elevated during infection with ADdlUL38 com-
pared to ADwt (Fig. 5A). Similar to ADdel29, we detected in-
creased p21CIP1 and decreased p53 protein expression using
Western blot analysis of lysates from ADdlUL38-infected cells
(Fig. 5B). The levels of expression for pUL123 were similar be-
tween viruses (Fig. 5B). Cumulatively, our data demonstrate that
pUL38 and pUL29/28 inhibit the expression of the p53-regulat-
able genes p21CIP1 and CASP1. Furthermore, elevated levels of
p21CIP1 in both the UL29- and UL38-deficient viral infections
correlated with reduced levels of p53.
pUL29/28 expression alters p53 binding and histone acetyla-
tion at the p21CIP1 and CASP1 promoters. The regulation of
p53 in cells involves diverse mechanisms. To determine how
pUL29/28 might influence p53, we explored several possibili-
ties, which included changes in acetylation of p53, relocaliza-
tion within the infected cells (17, 67), and modifications at
p53-regulatable promoters (reviewed in reference 68). We did
not detect changes either in p53 acetylation at lysine 382 be-
tween 6 and 24 hpi or in p53 localization between ADwt and
ADdel29 infections (data not shown). As previously seen for
the adenovirus E4-ORF3 protein (69), an alternative possibility
for p53 regulation involves changes occurring at selected p53-
responsive promoters. Using chromatin immunoprecipitation
(ChIP), we determined the levels of p21CIP1 and CASP1 pro-
moter sequences associating with p53 and acetylated histone
H3 during infection. Two p53 response elements (RE) have
been identified within the p21CIP1 promoter (Fig. 6A) (53)
and one in the CASP1 promoter (70). The 5= RE in the p21CIP1
promoter binds to p53 relatively strongly compared to the 3=
RE. To evaluate p53 binding, fibroblasts were serum starved
and then infected using either ADwt or ADdel29 virus at 6
IU/cell. We harvested the cells at 18 hpi, completed ChIP using
an antibody against p53 or control IgG, and determined
changes in the associating DNA by quantitative PCR. As a pos-
itive control, we treated uninfected cells with nutlin-3 and ob-
served increased DNA associated with p53 (Fig. 6A). Following
FIG 3 Disruption of pUL29/28 during infection results in elevated expression of a subset of p53-regulatable genes. (A) Fibroblasts were either mock infected or
infected with ADwt or ADdel29 at an MOI of 6 and harvested at the indicated times postinfection. Relative RNA was measured by qRT-PCR for the indicated
genes and normalized to cellular GAPDH levels. The data are the means for two technical replicates standard deviations, with the results being validated in a
separate independent biological replicate. Statistical analysis was performed using Student’s t test (*, P 0.05; **, P 0.01). (B) Experiments were completed as
described above, but no statistical difference in expression were observed.
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infection by ADdel29, we detected an average 3-fold increase in
DNA binding of p53 to the p21CIP1 5= RE compared to ADwt
(Fig. 6A). However, no changes were detected at the 3= RE (Fig.
6A). For the CASP1 promoter, we observed an average 2-fold
increase between viruses (Fig. 6A). Although modest, these
changes were detected in four replicate experiments. In con-
trast, we did not observe differences in binding to PUMA pro-
moter sequence or an exonic region of GAPDH (Fig. 6A). For
GAPDH, we did see an average increase in binding upon nut-
lin-3 treatment (Fig. 6A). However, these changes were highly
variable and were not statistically significant. Our data suggest
that p53 binding to the 5= RE of p21CIP1 promoter and the
CASP1 promoter is negatively influenced by the expression of
pUL29/28.
Acetylation of histone H3 on lysine 9 (H3K9Ac) is associated
with actively transcribed genes. We next quantified changes of
H3K9Ac at the p53-regulatable promoters during infection. Se-
rum-starved fibroblasts were infected with either ADwt or
ADdel29 virus at 5 IU/cell, andwe completed ChIP at 18 hpi using
an antibody against H3K9Ac. For both p21CIP1 and CASP1 pro-
moters, we detected increased DNA associated with H3K9Ac fol-
lowing infection with the UL29-deficient virus, compared to
ADwt (Fig. 6B). Specifically, we observed an average 2.3-fold in-
crease for the p21CIP1 5= RE, 1.4-fold for the 3= RE, and 16-fold
for the CASP1 promoter sequence (Fig. 6B). We did not observe
changes when using primers against PUMA and GAPDH (Fig.
6B). Although correlative, our data demonstrate increased p53
and H3K9Ac associating with p21CIP1 and CASP1 promoter se-
quences duringHCMV infection in the absence of the UL29ORF.
These data are consistent with the observations that p21CIP1 and
CASP1 RNA expression are elevated during an ADdel29 viral in-
fection compared to infection with the wild type.
DISCUSSION
Immediately upon HCMV infection, the steady-state amount of
cellular p53 protein, but not RNA, increases (19, 20, 22). Surpris-
FIG 4 pUL29/28 influences p21CIP1 andCASP1 expression during infection. (A) Fibroblasts were infected with ADwt or ADdel29 at anMOI of 6 and harvested
at the indicated times postinfection. Relative RNAwas measured using qRT-PCR. (B) Samples were collected at the indicated times postinfection and processed
forWestern blot analysis using antibodies against the indicated proteins. (C) For nutrient stress, fibroblasts were serum starved for 24 h and infected with ADwt
orADdel29 at anMOI of 6 in 7%FBS, 25mMglucose (hi) for 1 h. Cells were thenwashed and replenishedwith either normalmedium (hi) ormediumcontaining
5.56 mM glucose and no serum (lo). Western blot analysis was performed using whole-cell lysates harvested at the indicated times postinfection as well as from
mock-infected samples and antibodies against the indicated proteins.
FIG 5 HCMV pUL38 contributes to the regulation of p53 during infection.
(A) Fibroblasts were eithermock infected or infectedwithADwt orADdel38 at
anMOI of 5. At 18 hpi, RNAwas collected, and qRT-PCRwas used tomeasure
relative RNA levels normalized to GAPDH for the indicated genes. (B) Fibro-
blasts were either mock infected or infected with ADwt or ADdel38 and eval-
uated by Western blotting at 24 and 48 hpi using the indicated antibodies.
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ingly, however, the majority of p53-regulatable cellular genes are
not induced (19) (see Table S1 in the supplemental material). In
this study, we identified an interaction between p53 and the
HCMV protein pUL29/28 using a proteomics-based approach
(Table 1 and Fig. 1). With this discovery, we have demonstrated
that HCMV pUL29/28 and pUL38 contribute to negatively regu-
lating p53-dependent gene expression during infection for two of
eight genes examined more than 2-fold (Fig. 3). Recombinant
viruses containing disruptions in either UL29 or UL38 resulted in
elevated RNA levels for p21CIP1 (CDK-interacting protein 1) and
CASP1 (caspase 1) (Fig. 3A and 4A). Although our studies do not
comprehensively evaluate all p53-regulated genes, we observed that
additional genes were not significantly influenced by pUL29/28 and
pUL38 (Fig. 3B), suggesting that the regulation is limited.
In the absence of infection, pUL29/28 alone induced p21CIP1
expression in U2OS cells (Fig. 2A). However, we did not observe
any evidence of pUL29/28-mediated induction during infection
(Fig. 3A).When pUL29/28 was expressed with pUL38 again in the
absence of infection,maximal induction did not occur, suggesting
that pUL38may disrupt pUL29/28-p53 activities (Fig. 2A). Under
these conditions, both pUL29/28 and pUL38 likely interact with
p53 (Fig. 1B). Fromour studies usingU2OS cells, we can conclude
that pUL29/28 and pUL38 influence p53. However, because of the
artificial nature of the experiments and the absence of other viral
proteins, interpretation of the results as they pertain to HCMV
infection is not clear-cut. It is conceivable that pUL29/28 and
pUL38 function cooperatively as repressors of p53. In support of
this possibility, the interaction of p53 with pUL38 required ex-
pression of pUL29/28 (Fig. 1B).Wehave previously demonstrated
that the interaction between the pUL38 and NuRD complex also
requires pUL29/28 (46). Further support for a negative regulatory
role comes from the observation that infection in the absence of
UL29 resulted in increased association of p53 and acetylated his-
tone H3 K9 with the p21CIP1 and CASP1 promoters (Fig. 6A and
B). These results support the overall conclusion that pUL29/28 in
the context of pUL38 expression functions to inhibit two p53-
regulatable promoters during infection.
Expression of p21CIP1 was previously demonstrated to be
tightly regulated during infection (71). p21CIP1 contributes to
HCMV IE gene expression during infection of cells in G2/M (24).
Furthermore, HCMV pUL27 promotes p21CIP1 expression by
disrupting the Tip60 acetyltransferase (15). Our data demonstrate
that pUL29/28 and pUL38 also participate in regulating p21CIP1.
Initially, p21CIP1 protein levels are maintained within infected
cells up to 9 hpi (42, 71) and then begin to decrease. Regulation
occurs at the levels of both transcriptional control and protein
degradation (71). Here, we demonstrate that steady-state
p21CIP1 protein expression is maintained in the absence of
pUL29/28 (Fig. 4B and C) or pUL38 (Fig. 5B). Since these viral
proteins influence expression at the RNA level, our studies suggest
that transcriptional regulation plays a critical role in controlling
p21CIP1 during HCMV infection.
We have demonstrated that a subset of p53-regulatable genes is
influenced by pUL29/28 andpUL38. This indicates a role for other
HCMV proteins in regulating p53. Studies completed by several
laboratories have demonstrated the involvement of the immediate
early proteins IE1 (pUL123) and IE2 (pUL122) in regulating p53
activities (22, 35, 39–42, 44). Furthermore, pUL84 and pUL44
have also been implicated (42, 43). One challenge that we faced in
these studies was distinguishing between the role of pUL29/28 in
FIG 6 pUL29/28 influences p53 and histoneH3 K9 acetyl binding to responsive promoters. (A) Fibroblasts weremock infected, treated with 10Mnutlin-3 for
18 h, or infected with ADwt or ADdel29 at anMOI of 6 for 18 h. Chromatin immunoprecipitation (ChIP) was performed using an antibody against pan-p53 or
control IgG. Quantitative PCRwas used to determine the relative output DNA levels normalized to input. The data aremeans from four replicate experiments
standard deviations and are presented as percentage of input. The PUMA data set represents two experiments. (B) ChIP analysis was performed as described
above but using an antibody against histone 3 lysine 9 acetylation. The data are means for four replicates standard deviation and are presented as percentages
of input. Statistical analysis was performed using Student’s t test (*, P 0.05).
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influencingHCMV IE expression (46, 47) and direct regulation of
p53. In support of a direct role, we detected similar levels of IE1
protein expression in ADwt and both UL29- and UL38-deficient
viral infections using a high multiplicity of infection (Fig. 4B and
5B).We also demonstrated changes in in vitro promoter studies in
the absence of other HCMV proteins (Fig. 2A), and these changes
were consistent with the responses observed during infection (Fig.
3A). Furthermore, we showed that pUL29/28 interacts with p53
(Fig. 1A). However, we were unable to show direct association of
pUL29/28 with the responsive promoters due to high background
in ChIP experiments using the antibody against the FLAG epitope
(data not shown). Furthermore, the pUL29/28 binding partner
pUL38 regulates an endoplasmic reticulum stress response (72,
73) and mTOR activity (45), which may influence p53. Based
upon our data and the complexity of infection as well as p53 reg-
ulation, it is likely that our observations are the result of both
direct and indirect involvement with p53.
In addition to changes in gene expression, we observed in-
creased steady-state levels of p53 protein upon expression of
pUL29/28 and pUL38 following transfection (Fig. 2B). During
infection in the absence these protein, we detected reduced levels
of p53 protein (Fig. 4B and 5B). These changes coincided with
opposing changes in cellular gene expression in vitro (Fig. 2) and
during infection (Fig. 4 and 5). Therefore, we hypothesize that
pUL29/28 and pUL38 stabilize a population of p53 which is no
longer capable of binding to select promoters. A similar pheno-
type has been observed for adenovirus protein E4-ORF3 (69). Ex-
pression of E4-ORF3 results in stabilization of p53, whose activity
is dominantly suppressed. E4-ORF3 expression prevents p53
DNA binding by inducing heterochromatin formation at select
p53-regulatable promoters, including p21CIP1.
Numerous stress responses involving p53 are activated during
infection and have the potential to disrupt HCMV replication by
inducing response such as apoptosis, cell cycle arrest, or cellular
senescence. However, p53 is required for efficient HCMV gene
expression and viral replication (16). Therefore, regulating p53-
transcriptional responses during infection is critical. Our studies
indicate that pUL29/28 and pUL38 participate in repression of a
limited number of p53-regulated cellular genes during HCMV
infection.
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